Keywords: Vivalis, Human vaccine, EB66 cell line, License
Vivalis grants rights to EB66 cell line for human vaccine to unnamed company
Article | 15 April 2011
France-based biopharma company Vivalis (Euronext: VLS) says that it has signed a research agreement with an undisclosed worldwide vaccine company, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
